Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
作者： Seock-Ah Im , Jin Won Kim , Jin-Soo Kim , Min A. Kim , Bruce Jordan
DOI: 10.1097/PDM.0B013E3181FC02B7
关键词:
摘要: Despite recent advances in chemotherapy, the prognosis for patients with advanced gastric cancer (GC) or gastroesophageal junction remains poor. Human epidermal growth factor receptor 2 (HER2) is a novel target biologic therapy metastatic GC. We analyzed association between HER2 ov
wkhealth.com参考文章(1)
Y. Bang, H. Chung, J. Xu, F. Lordick, A. Sawaki, N. Al-Sakaff, O. Lipatov, C. See, J. Rueschoff, E. Van Cutsem, Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial Journal of Clinical Oncology. ,vol. 27, pp. 4556- 4556 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.4556